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Lingmin Zhang1†, Ning Wang2†, Suna Zhou3, Wenguang Ye4, Guixia Jing1* and Mingxin Zhang4*Abstract
Background: Propofol is one of the most commonly used intravenous anaesthetic agents during cancer resection
surgery, but the effect of propofol on gallbladder cancer is not clear. NF-E2-related factor 2 (Nrf2) is abundantly
expressed in cancer cells and relates to proliferation, invasion, and chemoresistance. The aims of the current study
were to evaluate effects of propofol on the behavior of human GC cells and role of Nrf2 in these effects.
Method: The effects of propofol on cell proliferation, apoptosis, and invasion were detected by MTT assays, flow
cytometry, and transwell assay. Also, activation of Nrf2 was determined by western blot, RT-PCR, and
immunofluorescence assays. Nrf2 was knocked-down in GBC-SD cells by shRNA before evaluating the role of Nrf2 in
the influence of propofol on biological behaviors.
Results: Propofol promoted the proliferation of GBC-SD cells in a dose- and time- dependent manner. After
exposure to propofol for 48 h, GBC-SD cells showed decreased apoptosis and increased invasion. Also, propofol
over-expressed Nrf2 at both the protein and mRNA levels and induced translocation of Nrf2 into the nucleus.
Finally, loss of Nrf2 by shRNA reversed the effect of propofol on cell proliferation, apoptosis, and invasion.
Conclusion: Propofol induces proliferation and promotes invasion of GC cells through activation of Nrf2.
Keywords: Propofol, NF-E2-related factor 2 (Nrf2), Gallbladder cancer, Proliferation, InvasionIntroduction
Propofol (2,6-diisopropylphenol), one of the most commonly
used intravenous anesthetic agents producing smooth induc-
tion and rapid recovery from anesthesia, has gained wide ac-
ceptance since its introduction in the late 80s [1]. Apart
from its multiple anesthetic advantages, propofol exerts a
number of non-anesthetic effects [2]. Interestingly, propofol
has antioxidant effects and preserves the endogenous organ
protective against ischemic or hypoxic injury. Heme
oxygenase-1 (HO-1) is involved in the mechanisms for organ
protection function of propofol [3-6]. However, HO-1 plays
an important role in cancer [7,8]. Some studies have sug-
gested a possible correlation between propofol and cancers,* Correspondence: jgx666@126.com; zmx3115@163.com
†Equal contributors
1Department of Anesthesiology, First Affiliated Hospital, Medical School, Xi'an
Jiaotong University, Xi’an, Shaanxi Province 710061, China
4Department of Gastroenterology, Tangdu Hospital, Fourth Military Medical
University, Xi'an, Shaanxi Province 710038, China
Full list of author information is available at the end of the article
© 2012 Zhang et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orbut the results are undefined [9-14]. Some studies revealed
that clinically relevant concentrations of propofol increased
the migration of breast carcinoma cells by activation of
GABA [9]. On the other hand, opposite results suggested
that these concentrations of propofol inhibited the invasion
of human cancer cells by modulating Rho A or ERK1/2
[10,11]. Other studies have demonstrated the effect of propo-
fol on immune response and metastasis in in vivo experi-
ments [12-14]. Considering the widely use of propofol in
clinic setting, it would be of great importance to investigate
the relationship between propofol and cancer.
NF-E2-related factor 2 (Nrf2) is a key transcription regula-
tor for antioxidant and detoxification enzymes, of which
HO-1 is the most important one [15,16]. Recent studies find
that Nrf2 is abundantly expressed in cancer cells and relates
to proliferation, invasion, and chemoresistance [17]. Our
early observations also found that expression of Nrf2 was
up-regulated in gallbladder cancer (GC) tissues and served
as an independent prognostic factor [18].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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regulation of HO-1, a downstream target gene of Nrf2.
We tested the hypothesis that propofol activates Nrf2,
hence it affects the progression of cancer. The aims of
the current study were to evaluate effects of propofol on
the behavior of human GC cells and role of Nrf2 in
these effects.
Materials and methods
Cell culture and reagents
Gallbladder carcinoma cells (GBC-SD) were obtained
from Shanghai Institute of Cell Biology, Chinese Acad-
emy of Sciences. Cells were cultured in RPMI 1640
media (Sigma, St. Louis, USA), supplemented with 10%
fetal bovine serum and 100 units/mL of penicillin and
streptomycin at 37°C in a humidified 5% CO2. Propofol
was purchased from Aldrich (Milwaukee, WI). Propofol
was diluted in dimethyl sulfoxide (DMSO, Sigma, St.
Louis, MO, USA) for in vitro assays.
Cell growth assay
The cells were seeded at a density of 5 × 103 cells/well in
96-well plates at a final volume of 180 μL in incubation, at
37°C, with 5% CO2. After different time incubation, 20 μL
of 5 mg/mL solution of MTT (Sigma, St. Louis, MO,
USA) in 1× PBS was added to each well. The plates were
then incubated for 4 h at 37°C. The reaction was then
solubilized in 100% DMSO, 20 μl/ well, and shaken for
15 min. Absorbance of each well was measured on a mul-
tidetection microplate reader (BMG LABTECH, Durham,
NC, USA) at a wavelength of 570 nm.
Apoptosis analysis
The cells were washed twice with cold 10 mM 1× PBS
and resuspended in 1× binding buffer (BD Biosciences,
San Jose, CA, USA). Apoptosis in GC cells was quanti-
fied by staining with annexin V-fluorescein isothiocyan-
ate (FITC) and propidium iodide (PI) [annexin
V-Phycoerythrin (PE) and 7-amino-actinomycin D (7-
AAD) for apoptosis analysis for cells transfected by
ShRNA vectors with the GFP fluorescence] The samples
were analyzed using flow cytometry (FACSCalibur, BD
Biosciences, San Jose, CA).
Cell invasion assay
For invasion assay, the membrane invasion culture sys-
tem (transwell membranes of 6.5 mm diameter and
8 μm pore size; Costar) was used according to the stand-
ard protocol. Briefly, harvested cells (1 × 105) resus-
pended in 100 μL of serum free RPMI 1640 were added
into the upper compartment of the chamber. A total of
1000 μL conditioned RPMI 1640 medium with 20% (v/v)
fetal bovine serum was used as a source of chemo-
attractant and placed in bottom compartment ofchamber. After 48 hours, the noninvasive cells on the
upper surface of the membrane were removed with a
cotton swab. The transformed cells that migrated
through the Matrigel matrix and stuck to the lower sur-
face of the membrane were fixed with 4% paraformalde-
hyde, stained with 1% crystal purple. The invasive cells
were then counted (five high-power fields/chamber)
using an inverted microscope (Olympus, Lake Success,
NY). Each tests repeated in triplicate.
RNA extraction and quantitative reverse transcription-PCR
(qRT-PCR)
Total RNA was isolated with Trizol reagent (Invitrogen,
Carlsbad, CA, USA) following the manufacturer’s instruc-
tion. qRT-PCR was carried out using a BioRad iQ5 Real-
Time PCR Detection System to confirm the expression
levels of mRNAs. In brief, the reverse transcription reac-
tion was carried out in a 20 μl volume with 1 μg of total
RNA, by incaution at 16°C for 30 min, 42°C for 42 min,
and 85°C for 5 min. 1 μl of the RT product was used in
each PCR. The PCR cycling began with template denature
at 95°C for 5 min, followed by 40 cycles of 95°C for 10 sec,
60°C for 20 sec, 72°C for 20 sec, and 78°C for 20 sec. Final
PCR products were resolved in agarose gen electrophor-
esis and a single band of expected size indicated the speci-
ficity of the reaction. Relative quantification was
performed using the 2-ΔΔCT [19]. Each PCR amplification
was performed in triplicate to verify the results. The Nrf2
primers were as follows: upstream 50-ACACGGTCCA
CAGCTCATC-30; and downstream 50-TGCCTCCAAG




Anti-Nrf2, anti-HO-1 and anti-β-actin antibodies were
obtained from Santa Cruz Biotech (Santa Cruz, CA,
USA). For Western blot analyses, 20 μg of total protein
were electrophoresed on a 10% SDS-PAGE gel, transferred
onto to PVDF membrane, blocked, and then incubated
with primary antibody as indicated above. Corresponding
horseradish peroxidase (HRP)-conjugated secondary anti-
body was then used on them at room temperature for
2 h. After chemiluminescence reaction with enhanced
ECL detection reagents (Amersham, Little Chalfont,
Buckinghamshire, England) according to the manufac-
turer’s instructions, the membranes were visualized by ex-
posure to X-ray film in dark. Densitometric analysis was
performed using Scion Image software (Scion Corpor-
ation, Frederick, MD).
Immunofluorescence assay
GBC-SD cells (5× 104 cells/mL) were grown on coverslips
in 24-well plates, with or without propofol stimulation.
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maldehyde, permeabilized with 0.3% Triton X-100, and
blocked with 5% bovine serum albumin (BSA), followed
by detection of Nrf2. After incubation with primary anti-
bodies against Nrf2 at 4°C overnight, cells were labeled
using FITC-conjugated secondary antibody (Santa Cruz
Biotechnology, Santa Cruz, CA). Finally, cells were stained
with DAPI (1 μg/ml, Roche, Shanghai, China) for nuclear
visualization. Immunoreactivity of each sample was
observed using a fluorescence microscope (Olympus,
Tokyo, Japan).
shRNA design and transfection
The sequences of the shRNAs were as follows: shRNA
867: 50-CACCGGTTGCCCA CATTCCCAAATCTTCA
AGAGAGATTTGGGAATGTGGGCAACCTTTTTT G-30;
shRNA 1118: 50-CACCGGGAGGAGCTATTATCCATTCFigure 1 Effects of propofol stimulation on cell proliferation, apoptosTTCAAGAGAGAATGGA TAATAGCTCCTCCCTTTT
TTG-30; shRNA 1757: 50-CACCGGGATATGGTACAA
CCCTTGTTTCAAGAGAACAAGGGTTGTACCATATC
CCTTTTTTG-30; shRNA 2019: 50-CACCGCAGTTCAAT
GAAGCTCAACTTTCAAGAGAAGTTGAGCTTC ATT
GAACTGCTTTTTTG-30. The pGP U6-shRNA plasmids
were constructed by cloning the respective shRNAs into
the pGPU6/GFP/ Neo vector (GenePharma, Shanghai,
China). An unrelated shRNA sequence (50-CACCGTTC
TCCGAACGTGT CACGTCAAGAGATTACGTGACAC
GTTCGGAGAATTTTTTG-30), with no homology to
any human gene, was used as a negative control (shNC).
GBC-SD cells were seeded in a 24-well plate at a con-
centration of 1 × 105 cells per well. Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA) was used for transfection
according to the instructions. Fresh growth medium was
changed 6 h after transfection and 48 h after transfectionis, and invasion.
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as a negative control. To verify the knockdown efficiency,
mRNA and protein of transfected cells were collected for
qRT-PCR and western blot analysis as described above.
Verification of Nrf2 knockdown was determined by nor-
malizing the levels of Nrf2 to the control.
Statistical analysis
Data are expressed as the mean± standard error from at
least 3 separate experiments performed in triplicate. Dif-
ferences between groups were assessed by unpaired, two-
tailed Student’s t test, P < 0.05 was considered significant.
Results
Effect of propofol on cell proliferation, apoptosis, and
invasion
We first investigated the effects of propofol on cell prolif-
eration, apoptosis, and invasion. The GBC-SD cell lines
were cultured in the presence of various concentrations of
propofol and the cell proliferation were measured by theFigure 2 Activation of Nrf2 by propofol stimulation.MTT assays. As shown in Figure 1A, the proliferation of
GBC-SD were promoted by propofol in dose- and time-
dependent manners. Propofol with the concentration
20 μmol/L and 40 μmol/L significantly promoted the pro-
liferation at 48 h and 72 h. To further quantify the cell
death, annexin V/PI analysis was performed. After
exposed to propofol for 48 h, GBC-SD cells showed de-
creasing apoptosis (Figure 1B and Figure 1C). Cell inva-
sion assay also revealed that propofol significantly
stimulated invasion when giving a concentration of
20 μmol/L and 40 μmol/L (Figure 1D and Figure 1E). So,
we chose propofol with the concentration 20 μmol/L in
the following experiments.
Cells were incubated with increasing concentrations of
propofol (0–40 μmol/L). (A) Propofol increased GBC-
SD cells proliferation in a time- and dose-dependent
manner. (B) and (C) Apoptosis analysis using flow cyto-
metry showed that propofol inhibited the apoptosis. (D)
and (E) Cell invasion assay revealed that propofol signifi-
cantly stimulated invasion. All of these results confirmed
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equal 20 μmol/L) significantly promoted proliferation,
inhibited apoptosis, and stimulated invasion. * P < 0.05
vs. Control (cells without propofol exposure).Activation of Nrf2 by propofol stimulation
We then evaluated the effect of propofol stimulation on ac-
tivation of Nrf2 in mRNA and protein levels. The results
showed that exposing to propofol (20 μmol/L) for 48 h up-
regulated the expression of Nrf2 at mRNAs levels
(Figure 2A). Besides, exposing to propofol (20 μmol/L) for
48 h also up-regulated the protein expression of both HO-
1 and Nrf2 (Figure 2B). Moreover, cells exposed to propofol
showed translocation of Nrf2 into the nucleus (Figure 2C).
(A) After stimulating by propofol, Nrf2 mRNA levels
were quantified by real-time PCR analysis. Data were
normalized by using GAPDH as an internal standard.
* P < 0.05 vs. Control (cells without propofol exposure).
These experiments were performed in triplicate. (B)
After stimulating by propofol, HO-1 and Nrf2 protein
level was analyzed by western blot. β-actin expression
was monitored as the internal standard. (C) AfterFigure 3 Knock-down of Nrf2 by specific shRNAs.stimulating by propofol, subcellular location of Nrf2 was
detected by immunofluorescence assay. Propofol stimu-
lation increased translocation of Nrf2 into the nucleus.Knock-down of Nrf2 by specific shRNAs
In order to knock down Nrf2, we constructed Nrf2-
shRNA recombinant plasmids and transfected them into
GBC-SD cells to knockdown the expression of Nrf2.
qRT-PCR and western blot showed that Nrf2 expression
was dramatically down-regulated at both the mRNA and
protein levels in GBC-SD cells compared with parental
cells and Sh-NC (Figure 3A and Figure 3B). Among the
four recombinant plasmids, ShRNA-1118 and ShRNA-
2019 has the highest suppression efficiency, so both of
them were used to process the following experiments.
Forty-eight hours after transfection, cells were har-
vested. (A) Nrf2 mRNA levels were quantified by real-
time PCR analysis. Data were normalized by using
GAPDH as an internal standard. *P < 0.05 vs. Control
(parental cells). (B) Nrf2 protein level was analyzed by
western blot. β-actin expression was monitored as the
internal standard.
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proliferation, apoptosis, and invasion
Finally, we examined whether loss of Nrf2 reversed the
effects of propofol on cell proliferation, apoptosis, and inva-
sion. Results showed that propofol alone and propofol plus
sh-NC significantly promoted proliferation, stimulated inva-
sion and inhibited apoptosis compared to parent cells. In
contrast, propofol with ShRNA-1118 and ShRNA-2019
reversed these effects (Figure 4A to Figure 4D).
After transfected by different vectors, GBC-SD cells
were incubated with propofol (20 μmol/L). (A) and (B)
The results of cell proliferation assay showed propofol
alone and propofol puls with sh-NC significantly pro-
moted proliferation and inhibited apoptosis, while pro-
pofol with ShRNA-1118 and ShRNA-2019 reversed
these effects. (C) and (D) Cell invasion assayFigure 4 Regulation of loss of Nrf2 for the effects of propofol on celldemonstrated that loss of Nrf2 reversed the effect of
propofol on invasion: propofol alone and propofol plus
sh-NC significantly stimulated invasion, while propofol
with ShRNA-1118 and ShRNA-2019 suppressed invasion
in GBC-SD cells. Each experiment was performed three
times in triplicate. * P < 0.05 vs. Control, # P < 0.05 vs.
Propofol. Control: parental cells; Propofol: parental cells
with propofol; NC+Propofol: cells transfected by ShNC
incubated with propofol; 1118 + Propofol: cells trans-
fected by ShRNA-1118 incubated with propofol;
2019 + Propofol: cells transfected by ShRNA-2019 incu-
bated with propofol.
Discussion
We evaluated effects of propofol on the behavior of
human GC cells and the role of Nrf2 in these effects.proliferation, apoptosis, and invasion.
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and invasion of gallbladder cancer cells through activa-
tion of Nrf2.
Anesthesia represents one of the most important med-
ical advances in history and is widely considered safe.
Nevertheless, numerous anesthetics are used for cancer
resection even if their effect on the behavior of cancer
cells is unclear [20]. Propofol is one of these anesthetics.
In in vivo experiments, different kinds of cancer cells
treated by different concentrations of propofol showed
divergent results. Garib et al. found that propofol
(34 μmol/L) increased migration of MDA-MB-468
breast carcinoma cells [9]. In contrast, Mammoto et al.
demonstrated that clinically relevant concentrations of
propofol (5.6-28 μmol/L) decreased the invasion ability
of human cancer cells (HeLa, HT1080, HOS and RPMI-
7951) [10]. Also, Miao et al. reported that propofol (at
45 μmol/L) stimulation inhibited invasion of LOVO
colon cancer cells [11]. So we set a concentration range
of propofol (0–40 μmol/L) to test its effect on the behav-
ior of GBC-SD cells. Our results showed that propofol
stimulation promoted proliferation by inhibiting apop-
tosis and increased the invasion ability.
Nrf2 belongs to the cnc (“cap ‘n’ collar”) subfamily of
the basic region leucine zipper transcription factors [21].
Nrf2 is a critical factor regulating cellular defense re-
sponse in many human pathological conditions. Upon
exposure of cells to oxidative stress or chemopreventive
compounds, Nrf2 translocates to the nucleus to activate
transcription of several different types of genes, including
those encoding endogenous antioxidants, phase II de-
toxifying enzymes, and transporters [22]. As one of Nrf2
downstream target genes, HO-1 is an antioxidant enzyme
that degrades prooxidant heme into ferrous iron, carbon
monoxide, and biliverdin [16]. HO-1 participates in the
mechanisms for organ protection function effect of many
intravenous and inhaled anesthetics including propofol
[5]. Since HO-1 is up-regulated by Nrf2 and propofol, we
then investigated whether propofol had an effect on the
activation of Nrf2. We found that propofol increased the
expression of Nrf2 both in mRNA and protein levels.
Further, immunofluorescence assay also confirmed that
Nrf2 translocated to nucleus after exposed to propofol.
Recent data has revealed the other side of Nrf2. Nrf2
over-expressed in many types of human cancer, giving
cancer cells an advantage for survival and growth. Fur-
ther studies show various genetic abnormalities of the
Nrf2 repressor, Keap1, in several cancer cell lines and
tumor tissues, including GC. Our previous studies also
demonstrated that Nrf2 was up-regulated in GC tissues
and high expression of Nrf2 related to poorer survival
[18]. Thus, we next evaluated the role of activation of
Nrf2 by propofol in its effect on behavior of human GC
cells. Through knockdown of expression of Nrf2 byshRNA, the effect of propofol on proliferation and apop-
tosis were reversed.
One important limitation of our study is short of
in vivo studies. There are also confused results about ef-
fect of propofol on immune response and metastasis
in vivo experiments [12-14]. It would be interesting and
important to clear the exact effect of propofol on GC in
animal model and clinic. These will be further explored
in future studies.
In conclusion, this study provides new insights into ef-
fect of propofol on behavior of GC cells and the related
mechanism. Our present study suggests that propofol
induces proliferation and promotes invasion of GC cells
through, at least partly, activation of Nrf2. It might there-
fore be speculated that propofol might not be the appro-
priate anaesthetic drug in the surgery of GC patients.
However, this should be verified in further studies, includ-
ing animal trials and prospective clinical studies.
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